MedTrace Logo

Protocol for Muscle Attenuation Cut-offs in Cirrhosis

NCT06593015 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1296

Last updated 2024-09-19

No results posted yet for this study

Summary

The goal of this observational study is to learn if new muscle attenuation cut-offs for the definition of myosteatosis can better predict survival in patients with cirrhosis. The main questions it aims to answer are:

* Can these new muscle attenuation cut-offs more accurately diagnose myosteatosis (fat infiltration in muscle mass ) in cirrhosis?
* Do these cut-offs work effectively across different patient groups, including men and women, those with obesity, and those with fluid retention in the abdomen?

Researchers will compare patients with cirrhosis from a retrospective Canadian cohort to those from a prospective Italian cohort to see if the new cut-offs predict survival better than existing ones\*\*.

Due to the retrospective nature of the study, no action is required from participants.

Conditions

  • Cirrhosis
  • Myosteatosis
  • Sarcopenia
  • Sarcopenia in Liver Cirrhosis
  • Portal Hypertension Related to Cirrhosis
  • Malnutrition

Interventions

DIAGNOSTIC_TEST

Radiological tool for the diagnosis of myosteatosis

Calculation of muscle attenuation at L3 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival

DIAGNOSTIC_TEST

Radiological tool for the diagnosis of myosteatosis

Calculation of muscle attenuation at L3/L4 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-12-01
Completion
2024-02-02

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06593015 on ClinicalTrials.gov